Publications by authors named "E I Elberri"
Tacrolimus versus hydrocortisone in management of atopic dermatitis in children, a randomized controlled double-blind study: New insights on TARC, CTACK, TSLP, and E-selectin.
Immun Inflamm Dis
November 2024
Introduction: Atopic dermatitis (AD) is a type of chronic inflammatory disorder that affects all age groups including children. AD is characterized by elevated inflammatory marker levels.
Aim: To assess the safety and effectiveness of topical tacrolimus ointment versus topical hydrocortisone cream in the treatment of pediatric AD by comparing the two treatments' ability to reduce serum cytokines.
Background: Ulcerative colitis (UC) is an idiopathic chronic inflammation of colonic and rectal mucosa. The peroxisome proliferator-activated receptor α (PPARα) has been identified as having protective effects in UC.
Aim: The study aimed to investigate the efficacy of fenofibrate, a PPARα agonist, in UC.
Corrigendum: Effect of a high dose atorvastatin as added-on therapy on symptoms and serum AMPK/NLRP3 inflammasome and IL-6/STAT3 axes in patients with major depressive disorder: randomized controlled clinical study.
Front Pharmacol
August 2024
Article Synopsis
- The text discusses a correction to a previously published article in the journal Pharmacology.
- The correction specifically addresses errors in the original study, ensuring accurate representation of the research findings.
- This update is important for maintaining the integrity of scientific literature and providing clear information to readers.
Introduction: Atopic dermatitis (AD) is a type of chronic inflammatory disorder that affects children.
Aim: To investigate whether hydrocortisone or tacrolimus could be more effective for treating AD in children.
Patients And Methods: This clinical randomized investigation included 100 children with AD who met the eligibility criteria.
Effect of a high dose atorvastatin as added-on therapy on symptoms and serum AMPK/NLRP3 inflammasome and IL-6/STAT3 axes in patients with major depressive disorder: randomized controlled clinical study.
Front Pharmacol
May 2024
Article Synopsis
- - The study explored how high doses of atorvastatin, a cholesterol-lowering drug known for its anti-inflammatory properties, can affect major depressive disorders (MDD) by analyzing various biological markers in patients.
- - In a trial with 60 MDD patients, those taking atorvastatin (80 mg) along with fluoxetine showed significantly greater improvements in depressive symptoms compared to those taking fluoxetine and a placebo, including better responses and higher remission rates.
- - The results suggest that atorvastatin might serve as an effective additional treatment for MDD by influencing specific inflammatory pathways, presenting a potential new avenue for depression therapy.